

CONFIDENTIAL DISCLOSURE AGREEMENT

This Confidential Disclosure Agreement (“**Agreement**”) is made effective as of the date of the last party to sign this Agreement (“**Effective Date**”)

Between:

ASTRAZENECA PHARMACEUTICALS LP, a Delaware limited partnership with offices at 1800 Concord Pike, Wilmington, Delaware 19803 (“**AstraZeneca**”); and

[Insert name and address of academic medical center] (“**AMC**”).

In consideration of the mutual covenants contained in this Agreement, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties, intending to be legally bound, agree as follows:

1) Definitions

“**Affiliate**” means with respect to a Person, any Person that directly, or indirectly through one or more intermediaries, controls, is controlled by or is under common control with such first Person. “**Control**” and, with correlative meanings, the terms “**controlled by**” and “**under common control with**” mean (a) the power to direct the management or policies of a Person, whether through ownership of voting securities or by contract relating to voting rights or corporate governance, resolution, regulation or otherwise, or (b) to own 50% or more of the outstanding voting securities or other ownership interest of such Person.

“**AMC Subject Matter**” means [REDACTED].

“**AstraZeneca Subject Matter**” means information related to AstraZeneca’s asset AZD [REDACTED] and/or the Purpose.

“**Confidential Information**” means, other than Exempt Information, any and all information or material in any form, including any documents, notes, analyses, studies, samples, drawings, flowcharts, databases, models, plans and software (including source and object codes), concerning a Disclosing Party’s Subject Matter that the Disclosing Party or any of its Representatives discloses to the Receiving Party or any of its Representatives pursuant to this Agreement, that is either marked “**Confidential**” or, if oral, declared to be confidential when disclosed and confirmed in writing within thirty (30) days of disclosure.

“**Disclosing Party**” means the party to this Agreement that discloses Confidential Information to the other party under this Agreement, either directly or indirectly through their respective Representatives.

“**Exempt Information**” means information that: (i) the Receiving Party or any of its Affiliates possessed before the Disclosing Party or any of its Representatives disclosed it under this Agreement; (ii) is or becomes publicly known (other than as a result of breach of this Agreement by the Receiving Party or any of its Representatives); (iii) the Receiving Party or any of its Affiliates obtains from a third party free of any confidentiality obligation to the Disclosing Party or its Affiliates with respect to such information; or (iv) is independently developed by or on behalf of the Receiving Party or any of its Affiliates without the use of the Disclosing Party’s Confidential Information.

“**Person**” means an individual, sole proprietorship, partnership, limited partnership, limited liability partnership, corporation, limited liability company, business trust, joint stock company, trust, incorporated association, joint venture or similar entity or organization, including a government or political subdivision, department or agency of a government.

“Purpose” means the purpose of enabling the parties to evaluate the merits and feasibility of entering into a collaborative research agreement between AstraZeneca or one or more of its Affiliates on the one hand and AMC on the other, and preparing a project plan in support of a grant application to the National Center for Advancing Translational Sciences (“NCATS”) under the U.S. National Institutes of Health (“NIH”).

“Receiving Party” means the party to this Agreement that receives Confidential Information from the other party under this Agreement, either directly or indirectly through their respective Representatives.

“Representatives” means, with respect to a party to this Agreement, its Affiliates and its and their respective directors, officers, employees, contractors, consultants, advisors and agents.

2) Treatment of Confidential Information

- (a) The Receiving Party shall maintain the confidentiality of the Disclosing Party’s Confidential Information with at least the same degree of care as it maintains the confidentiality of its own confidential information, and in any event, not less than a reasonable standard of care.
- (b) The Receiving Party may use, copy and make extracts of the Disclosing Party’s Confidential Information only in connection with the Purpose.
- (c) The Receiving Party shall not disclose any of the Disclosing Party’s Confidential Information to any third party other than the Receiving Party’s Representatives who have a need to know the Confidential Information for the Purpose and who are bound by obligations of confidentiality substantially similar to those in this Agreement, *provided, however*, that AMC may disclose AstraZeneca’s Confidential Information to the NIH as necessary to support the grant application described in the Purpose, subject to applicable laws, regulations and NIH policies concerning confidentiality.
- (d) Upon the Disclosing Party’s request, the Receiving Party shall promptly return to the Disclosing Party or destroy all copies of the Disclosing Party’s Confidential Information. Upon the Disclosing Party’s request, the Receiving Party shall confirm in writing such destruction.
- (e) Section 2(d) notwithstanding, the Receiving Party: (i) may retain a single copy of the Disclosing Party’s Confidential Information for the sole purpose of ascertaining its ongoing rights and responsibilities in respect of such information; and (ii) shall not be required to destroy any computer files stored securely by the Receiving Party or its Representatives that are: (x) created during automatic system back up; or (y) retained for legal purposes by the legal department of the Receiving Party and its Affiliates.
- (f) Anything to the contrary contained herein notwithstanding, the Receiving Party shall be permitted to disclose (and the Receiving Party shall not be required to destroy) any of the Disclosing Party’s Confidential Information that is required or requested to be disclosed by a governmental authority or applicable law in connection with a legal or administrative proceeding (including in connection with any regulatory approval process), provided that the Receiving Party shall: (i) notify the Disclosing Party of any such disclosure requirement as soon as practicable; (ii) cooperate with the Disclosing Party (at the Disclosing Party’s cost) if the Disclosing Party seeks a protective order or other remedy in respect of any such disclosure and (iii) furnish only that portion of the Confidential Information that the Receiving Party is legally required to disclose.

3) Disclosure Term and Termination of Obligations

The term during which disclosures may be made and received under this Agreement will be two (2) years from the Effective Date. The Receiving Party’s obligations under this Agreement terminate seven (7) years after the Effective Date of this Agreement.

4) No Representation or Warranty

ALL CONFIDENTIAL INFORMATION IS PROVIDED "AS IS" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW DISCLOSING PARTY HEREBY DISCLAIMS AND EXCLUDES ANY AND ALL REPRESENTATIONS, WARRANTIES, CONDITIONS OR OTHER TERMS, WHETHER WRITTEN OR ORAL, EXPRESSED OR IMPLIED, WITH RESPECT TO THE CONFIDENTIAL INFORMATION IT PROVIDES HEREUNDER, INCLUDING ANY REPRESENTATION OR WARRANTY OF ACCURACY, COMPLETENESS, QUALITY, PERFORMANCE, MERCHANTABILITY OR FITNESS FOR A PARTICULAR USE OR PURPOSE OR NON-INFRINGEMENT. The Disclosing Party shall not have any liability, direct or indirect, to the Receiving Party for any damages that may arise as a result of the Receiving Party's use of Confidential Information or any errors therein or omissions therefrom.

5) Other Matters

- (a) Neither this Agreement nor the performance by either party hereunder shall transfer to the Receiving Party any proprietary right, title, interest or claim in or to any of the Disclosing Party's Confidential Information (including any intellectual property rights subsisting therein).
- (b) Neither party is obligated to negotiate or enter into any other agreement, and any discussions may be terminated at the sole discretion of either party at any time and for any reason.
- (c) This Agreement sets forth the parties' entire understanding about its subject matter and supersedes any other agreement or understanding between the parties about its subject matter. Neither party can assign, amend, or terminate any part of this Agreement except in writing signed by both parties.
- (d) If a court or other tribunal of competent jurisdiction should hold any term or provision of this Agreement to be excessive, invalid, void or unenforceable, the offending term or provision shall be deleted or revised to the extent necessary to be enforceable, and, if possible, replaced by a term or provisions which, so far as practicable, achieves the legitimate aims of the parties.
- (e) This Agreement may be executed in two counterparts (including by facsimile or electronic copies), each of which shall be deemed an original, and both of which together shall constitute one and the same instrument.
- (f) The interpretation and construction of this Agreement shall be governed by the law of the State of Delaware, excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction. Subject to Section 5(g), the parties hereby irrevocably and unconditionally consent to the exclusive jurisdiction of the state and federal courts for the State of Delaware for any action, suit or proceeding arising out of or relating to this Agreement, and agree not to commence any action, suit or proceeding related thereto except in such courts. The parties irrevocably and unconditionally waive their right to a jury trial.
- (g) A breach by either party of this Agreement may cause irreparable damage for which the non-breaching party will not be adequately compensated by monetary damages. In the event of a breach, or threatened breach, of this Agreement, the non-breaching party shall be entitled to seek equitable relief from any court of competent jurisdiction, whether preliminary or permanent, without the requirement of having to post a bond or other security. Nothing in this Section 5(g) is intended, or shall be construed, to limit the parties' rights to any other remedy for a breach of any provision of this Agreement.

IN WITNESS WHEREOF, duly-authorized representatives of the parties have signed as of the Effective Date.

Signed on behalf of AstraZeneca

Signed on behalf of [AMC]

By: _____

By: _____

Print Name: Dr. Donald Frail

Print Name: _____

Title: VP, Emerging Innovations
(Duly authorized)

Title: _____
(Duly authorized)

Date: _____

Date: _____